Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1982 2
1984 4
1986 1
1987 1
1988 1
1990 1
1993 2
1994 3
1995 1
1996 1
2000 1
2002 5
2005 1
2006 4
2008 1
2009 1
2010 2
2011 5
2012 2
2013 4
2014 4
2015 2
2016 4
2017 2
2018 4
2019 4
2020 3
2021 6
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Nath K, Lee J, Elko TA, Levy L, Preston E, Devlin SM, Ponce DM, Lin RJ, Shaffer BC, Cho C, Politikos I, Jakubowski AA, Park JH, Rampal R, Perales MA, Tallman MS, Barker JN, Berman E, Tamari R, Stein E, Giralt SA, Gyurkocza B. Nath K, et al. Am J Hematol. 2023 Dec;98(12):1869-1876. doi: 10.1002/ajh.27084. Epub 2023 Sep 9. Am J Hematol. 2023. PMID: 37688521
Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrolled at the time of induction/reinduction therapy. ...
Between April 2016 and April 2021, adult patients with newly diagnosed or relapsed/refractory acute leukemia were enrol …
The combination of clofarabine, etoposide, and cyclophosphamide shows limited efficacy as a bridge to transplant for children with refractory acute leukemia: results of a monitored prospective study.
Toporski J, Król L, Dykes J, Håkansson Y, Pronk C, Turkiewicz D. Toporski J, et al. Pediatr Hematol Oncol. 2021 Apr;38(3):216-226. doi: 10.1080/08880018.2020.1838012. Epub 2020 Nov 5. Pediatr Hematol Oncol. 2021. PMID: 33150834 Clinical Trial.
We conducted a prospective trial (clinicval.trials.gov NCT01025778) to explore the use of clofarabine-based chemotherapy as a bridge-to-transplant approach. Children with refractory acute leukemia were enrolled to receive two induction courses of clofarabine, …
We conducted a prospective trial (clinicval.trials.gov NCT01025778) to explore the use of clofarabine-based chemotherapy as a bridge-to-tran …
Idarubicin in refractory acute leukemia.
Fülle HH, Hellriegel KP. Fülle HH, et al. Onkologie. 1986 Jun;9(3):152-3. doi: 10.1159/000215992. Onkologie. 1986. PMID: 3528962 Free article.
Single-Arm Non-Blinded Multicenter Clinical Trial on T-Cell-Replete Haploidentical Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin for Relapsed and Refractory Pediatric Acute Leukemia.
Kada A, Kikuta A, Saito AM, Kato K, Iguchi A, Yabe H, Ishida H, Hyakuna N, Takahashi Y, Nagasawa M, Hashii Y, Umeda K, Matsumoto K, Fujisaki H, Yano M, Nakazawa Y, Sano H. Kada A, et al. Kurume Med J. 2021 Oct 6;66(3):161-168. doi: 10.2739/kurumemedj.MS663004. Epub 2021 Aug 20. Kurume Med J. 2021. PMID: 34421094 Free article.
Multicenter single-arm clinical trials of T-cell replete haploidentical stem cell transplantation (TCR-haplo-SCT) will be conducted in children with relapsed and refractory acute leukemia. After myeloablative conditioning using total body irradiation or busul …
Multicenter single-arm clinical trials of T-cell replete haploidentical stem cell transplantation (TCR-haplo-SCT) will be conducted in child …
Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
Moiseev I, Bondarenko S, Morozova E, Vlasova Y, Dotsenko A, Epifanovskaya O, Babenko E, Botina A, Baykov V, Surkova E, Lapin S, Beynarovich A, Borzenkova E, Golosgchapov O, Kanunnikov M, Kudyasheva O, Ovechkina V, Pirogova O, Porunova V, Rudakova T, Smikova O, Smirnova A, Afansyev B. Moiseev I, et al. Transplant Cell Ther. 2021 Jul;27(7):601.e1-601.e7. doi: 10.1016/j.jtct.2021.03.032. Epub 2021 May 7. Transplant Cell Ther. 2021. PMID: 33845259 Free article.
Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.
Buaboonnam J, Cao X, Pauley JL, Pui CH, Ribeiro RC, Rubnitz JE, Inaba H. Buaboonnam J, et al. Pediatr Blood Cancer. 2013 Jul;60(7):1161-4. doi: 10.1002/pbc.24470. Epub 2013 Jan 17. Pediatr Blood Cancer. 2013. PMID: 23335430 Free PMC article.
BACKGROUND: The efficacy of combination chemotherapy with methotrexate (MTX) and asparaginase is not well known in relapsed and refractory acute leukemia after contemporary therapy. PROCEDURE: A retrospective study of pediatric patients with relapsed or refra …
BACKGROUND: The efficacy of combination chemotherapy with methotrexate (MTX) and asparaginase is not well known in relapsed and refractor …
Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
Kobayashi S, Kanda Y, Konuma T, Inamoto Y, Matsumoto K, Uchida N, Ikegame K, Miyamoto T, Doki N, Nakamae H, Katayama Y, Takahashi S, Shiratori S, Saito S, Kawakita T, Kanda J, Fukuda T, Atsuta Y, Kimura F. Kobayashi S, et al. Bone Marrow Transplant. 2022 Jan;57(1):43-50. doi: 10.1038/s41409-021-01485-6. Epub 2021 Oct 8. Bone Marrow Transplant. 2022. PMID: 34625663
Thus, herein a retrospective analysis of 253 allo-HSCT3s in patients with relapsed/refractory acute leukemia was carried out. In total, 29 (11.5%) survived at a median follow-up of 794 days (range: 87-4 619). ...Complete remission at allo-HSCT3, performance s …
Thus, herein a retrospective analysis of 253 allo-HSCT3s in patients with relapsed/refractory acute leukemia was carrie …
HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
Higuchi K, Sawada A, Kondo O, Okada Y, Tsujimoto H, Ioi A, Mayumi A, Shimizu M, Sato M, Goto K, Inoue S, Yasui M, Inoue M. Higuchi K, et al. Int J Hematol. 2022 Mar;115(3):406-413. doi: 10.1007/s12185-021-03270-z. Epub 2022 Jan 14. Int J Hematol. 2022. PMID: 35028882
Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia.
Konishi T, Doki N, Nagata A, Yamada Y, Takezaki T, Kaito S, Kurosawa S, Sakaguchi M, Harada K, Yasuda S, Yoshioka K, Inamoto K, Toya T, Igarashi A, Najima Y, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K. Konishi T, et al. Ann Hematol. 2020 Jan;99(1):147-155. doi: 10.1007/s00277-019-03865-x. Epub 2019 Nov 30. Ann Hematol. 2020. PMID: 31786646 Clinical Trial.
Allogeneic hematopoietic stem cell transplantation (HSCT) could be the only curative therapy for patients with relapsed/refractory acute leukemia (RRAL). Many reports have described unmanipulated haploidentical HSCT (HID-HSCT) using high-dose antithymocyte gl …
Allogeneic hematopoietic stem cell transplantation (HSCT) could be the only curative therapy for patients with relapsed/refractory …
69 results